| |
| |
|
| Insider
Information: |
Altshuler David |
| Relationship: |
EVP, Chief Scientific... |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
25,813 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$11,436,450 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
25,813 |
|
|
| Total
Value |
$11,436,450 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Chief Scientific... |
2024-05-15 |
25,813 |
2014-07-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
157 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-20 |
4 |
D |
$420.58 |
$1,182,671 |
D/D |
(2,812) |
41,026 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-10 |
4 |
D |
$214.16 |
$636,912 |
D/D |
(2,974) |
58,381 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-21 |
4 |
AS |
$421.77 |
$1,266,154 |
D/D |
(3,002) |
34,022 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-25 |
4 |
AS |
$229.72 |
$706,776 |
D/D |
(3,028) |
28,902 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2021-02-25 |
4 |
AS |
$211.58 |
$646,139 |
D/D |
(3,028) |
33,589 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2020-02-18 |
4 |
AS |
$241.80 |
$762,201 |
D/D |
(3,128) |
34,346 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-12 |
4 |
AS |
$420.24 |
$1,321,655 |
D/D |
(3,145) |
47,588 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-17 |
4 |
D |
$232.51 |
$799,602 |
D/D |
(3,439) |
53,999 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-10 |
4 |
D |
$294.33 |
$1,018,676 |
D/D |
(3,461) |
65,184 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
Director |
– • – |
2014-11-28 |
4 |
AS |
$119.75 |
$419,125 |
D/D |
(3,500) |
0 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
Director |
– • – |
2014-11-28 |
4 |
OE |
$59.55 |
$212,015 |
D/D |
3,500 |
3,500 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2022-02-10 |
4 |
D |
$237.74 |
$836,369 |
D/D |
(3,518) |
62,179 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-10-22 |
4 |
AS |
$194.37 |
$713,144 |
D/D |
(3,669) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-10-22 |
4 |
OE |
$155.57 |
$570,786 |
D/D |
3,669 |
35,222 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-17 |
4 |
D |
$292.85 |
$1,098,188 |
D/D |
(3,750) |
44,248 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-16 |
4 |
D |
$424.01 |
$1,590,038 |
D/D |
(3,750) |
43,838 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-25 |
4 |
OE |
$187.53 |
$733,242 |
D/D |
3,910 |
35,463 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-25 |
4 |
AS |
$219.37 |
$857,737 |
D/D |
(3,910) |
31,553 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-24 |
4 |
D |
$289.12 |
$1,147,806 |
D/D |
(3,970) |
36,276 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-23 |
4 |
D |
$431.79 |
$1,714,206 |
D/D |
(3,970) |
30,052 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2023-02-21 |
4 |
AS |
$291.01 |
$1,175,676 |
D/D |
(4,002) |
40,246 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2024-02-20 |
4 |
AS |
$420.79 |
$1,684,002 |
D/D |
(4,002) |
37,024 |
0 |
% |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-02-04 |
4 |
OE |
$86.52 |
$365,117 |
D/D |
4,126 |
41,443 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-02-04 |
4 |
AS |
$189.19 |
$780,598 |
D/D |
(4,126) |
39,113 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
• – – |
2019-11-04 |
4 |
AS |
$200.26 |
$827,049 |
D/D |
(4,126) |
31,553 |
0 |
- |
|
157 Records found
|
|
Page 4 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
